Biohaven Ltd. (BHVN) AI Stock Analysis

• Market Cap: $2.08B
• Dividend Yield: N/A
• Average Volume (3M): 1.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: N/A
• EPS Growth: -65.63%
• Country: US
• Employees: 256
• Sector: Healthcare
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -9.39
• Shares Outstanding: 102,065,000
• 10 Day Avg. Volume: 1,871,254
• 30 Day Avg. Volume: 1,457,325
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -4.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $63.33
• Price Target Upside: 208.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

Biohaven Ltd. faces significant financial challenges with zero revenue and negative cash flow, resulting in a low financial performance score. Technical indicators suggest bearish momentum, further weighing down the overall score. The lack of profitability and income potential is reflected in a poor valuation score. The overall stock score is low, highlighting the company's need to improve its financial and operational standing to attract investor interest.

Positive Factors

Clinical Trials

Strong IgG reductions reaffirm BHV-1300’s therapeutic potential and place in the FcRn targeting space.

Product Development

The company plans to develop BHV-1300 in an autoinjector format, which is important for commercial success given the competitive landscape.

Regulatory Approval

There is increasing confidence in the likelihood of FDA approval for troriluzole in SCA, which is seen as a potential catalyst for the company.

Negative Factors

Clinical Trial Results

BHV-7000 Ph2 data was negative, as it failed to reach statistical significance in bipolar mania.

Financial Concerns

Biohaven has a high cash burn rate and an arguably overbroad R&D program, making the stock look expensive for its current state.

Regulatory Challenges

The SCA approval is far from derisked as the drug has previously received a CRL due to failure in the original placebo-controlled trial.

Biohaven Ltd. Business Overview & Revenue Model

Company Description

Biohaven Ltd. (BHVN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for neurological and neuropsychiatric diseases. The company operates in the healthcare sector and specializes in addressing unmet medical needs within the central nervous system (CNS) disorders. Biohaven's core products include FDA-approved treatments for migraine and other CNS conditions, leveraging its proprietary platforms and extensive research capabilities.

How the Company Makes Money

Biohaven Ltd. generates revenue primarily through the sale of its pharmaceutical products designed to treat neurological and neuropsychiatric diseases. The company's key revenue streams include sales from its approved drugs, particularly in the migraine treatment market. Biohaven may also earn income through licensing agreements, where it partners with other pharmaceutical companies to distribute its products in various regions. Additionally, the company could be involved in collaborative research and development agreements, which may provide milestone payments and royalties, contributing to its earnings.

Biohaven Ltd. Financial Statement Overview

Summary

Biohaven Ltd. faces financial challenges with zero revenue and significant operational losses. The balance sheet shows stability in equity but limited growth in assets. Cash flow analysis reveals persistent negative free cash flow and reliance on financing activities. Overall, the financial health remains weak, with a need for revenue growth and improved cash generation.

Income Statement

Biohaven Ltd. has consistently reported zero revenue in recent years, indicating a lack of product sales or service income. The company has faced significant losses with net income remaining negative, reflecting ongoing operational challenges. This lack of revenue generation alongside substantial losses results in a low income statement score.

Balance Sheet

The balance sheet reveals a relatively stable equity position with stockholders' equity remaining positive. However, the debt-to-equity ratio has been manageable due to low levels of debt. Despite positive cash balances, the company’s equity ratio is impacted by limited asset growth. The overall financial position is stable but lacks significant improvement, contributing to a moderate score.

Cash Flow

Operating cash flow is consistently negative, indicating ongoing cash outflows from core operations. Free cash flow remains negative, reflecting challenges in generating cash after capital expenditures. The cash flow score is limited by the lack of positive cash generation, although financing inflows have supported liquidity.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	462.51M	0.00
	Gross Profit
0.00	-3.37M	-1.39M	370.85M	-72.00K
	EBIT
-885.11M	-436.05M	-567.93M	-218.90M	-114.51M
	EBITDA
-885.11M	-429.14M	-462.80M	-217.51M	-114.43M
	Net Income Common Stockholders
-846.42M	-408.17M	-570.28M	-213.80M	-118.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
485.99M	381.82M	465.34M	76.06M	82.51M
	Total Assets
615.11M	513.21M	661.78M	142.06M	111.50M
	Total Debt
32.78M	30.88M	30.58M	626.72M	267.46M
	Net Debt
-66.35M	-217.53M	-174.30M	550.66M	184.95M
	Total Liabilities
191.67M	85.24M	123.01M	47.37M	34.72M
	Stockholders Equity
423.44M	427.98M	538.77M	34.69M	16.78M
Cash Flow		Free Cash Flow
-586.50M	-334.77M	-338.76M	-146.78M	-78.65M
	Operating Cash Flow
-582.45M	-331.73M	-297.69M	-145.84M	-75.96M
	Investing Cash Flow
-244.97M	129.83M	-304.79M	944.00K	-2.70M
	Financing Cash Flow
677.77M	211.91M	767.60M	138.45M	152.24M

Biohaven Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 20.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BHVN, the sentiment is Negative. The current price of 20.55 is below the 20-day moving average (MA) of 21.50, below the 50-day MA of 28.95, and below the 200-day MA of 38.90, indicating a bearish trend. The MACD of -2.70 indicates Negative momentum. The RSI at 42.89 is Neutral, neither overbought nor oversold. The STOCH value of 88.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BHVN.

Biohaven Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGND	69 Neutral	$2.02B	48.01	-0.53%	―	27.28%	-101.63%
KNSA	59 Neutral	$1.46B	―	-9.85%	―	56.60%	-403.56%
ARQT	57 Neutral	$1.54B	―	-113.76%	―	229.74%	70.23%
TARS	54 Neutral	$2.02B	―	-54.83%	―	948.62%	33.12%
Sector *	50 Neutral	$5.14B	3.10	-40.94%	2.95%	17.94%	2.00%
NAMS	47 Neutral	$1.79B	―	-61.35%	―	―	―
BHVN	35 Underperform	$2.08B	―	-198.83%	―	―	-65.63%

Biohaven Ltd. Corporate Events

Biohaven Showcases TRAP Degraders at J.P. Morgan Conference

Biohaven Ltd. announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its integrated discovery engine and the advancement of its next-generation TRAP Degraders, which selectively remove disease-causing proteins. The company presented new clinical data showing the potential of BHV-1400 to treat IgA Nephropathy by effectively removing galactose-deficient IgA1 while preserving normal immune function, showcasing its innovative approach to targeting specific pathogenic species with minimal side effects.